Holen Sie sich die Stockscreener-App
0.1276
8.86%
-0.0124
Handel nachbörslich:
.13
0.0024
+1.88%
Schlusskurs vom Vortag:
$0.14
Offen:
$0.1373
24-Stunden-Volumen:
2.25M
Relative Volume:
0.95
Marktkapitalisierung:
$6.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-63.25%
1M Leistung:
-69.61%
6M Leistung:
-79.75%
1J Leistung:
-87.73%
1-Tages-Spanne:
$0.1237
$0.1398
1-Wochen-Bereich:
$0.1237
$0.4672
52-Wochen-Spanne:
$0.1237
$1.82
Cellyan Biotechnology Co Ltd Stock (HKPD) Company Profile
Firmenname
Cellyan Biotechnology Co Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare HKPD vs MCK, COR, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HKPD
Cellyan Biotechnology Co Ltd
|
0.1276 | 19.84M | 0 | 0 | 0 | 0.00 |
MCK
Mckesson Corp
|
907.99 | 97.79B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
330.95 | 60.05B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
247.18 | 53.13B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
89.81 | 9.86B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
0.848 | 873.84M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cellyan Biotechnology Co Ltd Aktie (HKPD) Neueste Nachrichten
12 Industrials Stocks Moving In Tuesday's After-Market Session - Benzinga
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - FinancialContent
12 Industrials Stocks Moving In Tuesday's Intraday Session - Benzinga
Cellyan Biotechnology (HKPD) Advances 3.61% as Shares Approach Key $0.44 ResistanceMA Cross Alert - vinanet.vn
Kam Leung Chan Net Worth (2026) - GuruFocus
Jingyan Wu Net Worth (2026) - GuruFocus
Shu Liu Net Worth (2026) - GuruFocus
Chenyu Andy Liang Net Worth (2026) - GuruFocus
Zifeng Wang Net Worth (2026) - GuruFocus
Mike Yao Zhou Net Worth (2026) - GuruFocus
Cellyan Biotechnology granted Nasdaq compliance extension; shares surge - MSN
Cellyan Biotechnology stock sinks 21% after hours: Here's what happened - MSN
12 Industrials Stocks Moving In Friday's Pre-Market Session - Benzinga
Cellyan Biotechnology Wins Second Nasdaq Grace Period to Fix Sub-$1 Share Price - TipRanks
Cellyan Biotechnology Stock Sinks 21% After Hours: Here's What Happened - Benzinga
Cellyan Biotechnology Gets 180-Day Nasdaq Grace Period on Bid-Price Rule - marketscreener.com
Cellyan Biotechnology gets 180-day extension for Nasdaq compliance By Investing.com - Investing.com Nigeria
12 Industrials Stocks Moving In Thursday's After-Market Session - Benzinga
Thursday's after hours session: top gainers and losers - ChartMill
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period - The Manila Times
Cellyan Biotechnology gets 180-day extension for Nasdaq compliance - Investing.com
Cellyan Biotechnology Receives Nasdaq Extension to Regain Minimum Bid Price Compliance - Quiver Quantitative
Nasdaq grants Cellyan Biotechnology (Nasdaq: HKPD) bid-price extension - Stock Titan
Cellyan Biotechnology Must Reach $1 Bid Price by Jan. 11 - Stock Titan
Cellyan Biotech (HKPD) Holds Steady Near Support After Minor DeclineMA Cross Alert - dars.gov.et
12 Industrials Stocks Moving In Wednesday's Intraday Session - Benzinga
12 Industrials Stocks Moving In Tuesday's Pre-Market Session - Benzinga
[EFFECT] Cellyan Biotechnology Co., Ltd SEC Filing - Stock Titan
Cellyan Biotechnology (HKPD) Slides 3.78% to $0.40 as Biotech Volatility PersistsBox Spread - dars.gov.et
Cellyan Biotech (HKPD) Slides 7.6%, Testing Key Support at $0.39Channel Projection - newsline.com
Cellyan Biotechnology (NASDAQ: HKPD) files $200M shelf to sell shares, debt - Stock Titan
Cellyan Biotechnology (HKPD) director CHAN Kam Leung files initial Form 3 - Stock Titan
12 Industrials Stocks Moving In Wednesday's After-Market Session - Benzinga
[Form 3] Cellyan Biotechnology Co., Ltd Initial Statement of Beneficial Ownership - Stock Titan
Cellyan Biotechnology (HKPD) Chief Strategy Officer listed with no Form 3 transactions - Stock Titan
Cellyan Biotechnology (HKPD) CFO Liu Shu files initial ownership Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Zhou Mike Yao files initial Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Wu Jingyan submits initial SEC Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) CEO and director files Form 3 with no share transactions - Stock Titan
Cellyan Biotechnology (HKPD) Slumps 7.83%: Key Support at $0.50 Under PressureFibonacci Fan - The Legal Advocate
Cellyan Biotechnology (HKPD) Holds Steady Near Support After Marginal GainsAdvance Decline Volume - The Legal Advocate
HKPDCellyan Biotechnology Co Ltd Stock Price and Quote - Finviz
Cellyan Biotechnology (HKPD) Drops 3.6% as Shares Approach Critical $0.50 SupportButterfly Setup - The Legal Advocate
Cellyan Biotechnology Faces Resistance at $0.57 After Recent DeclineSeasonality Effect - po-news-eg.net
12 Industrials Stocks Moving In Wednesday's Pre-Market SessionBrenmiller Energy (NASDAQ:BNRG), Smart P - Benzinga
Cellyan (HKPD) quarterly earnings report shows no revenue, EPS data available amid biotechnology sector headwinds.Shared Buy Zones - Newser
What net volume Cellyan (HKPD)? (Smart Money Outflows) 2026-04-29Buy Signals - newser.com
What leverage Cellyan (HKPD)? | HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressSocial Trading Insights - newser.com
HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressPretax Income Report - The Legal Advocate
HKPD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HKPD (Cellyan) posts 21.7 percent Q2 2025 revenue growth, shares drop 6.58 percent amid negative earnings.Dividend Increase Stocks - The Legal Advocate
Finanzdaten der Cellyan Biotechnology Co Ltd-Aktie (HKPD)
Es liegen keine Finanzdaten für Cellyan Biotechnology Co Ltd (HKPD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.59%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):